Results 321 to 330 of about 47,925,041 (381)

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Periodontitis and Acute Myocardial Infarction Among Patients Visiting a Tertiary Care Center in Koshi Province of Nepal: A Case-Control Study. [PDF]

Int J Dent
Limbu B, Shrestha A, Bhagat T, Agrawal SK, Pandey NK.   +4 more
europepmc   +1 more source

Competing in the Chinese Instant Noodle Market - A market research on the "Present Wheater" brand of the Hualong Group Co., Ltd

, 2005
Yanni Shizhou, Shishang Gu
openalex   +1 more source

Poster Presentation

Experimental Animals, 2018
openaire   +3 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Tumor-associated high endothelial venules are associated with enhanced lymphocyte infiltration and favorable prognosis in resected hepatocellular carcinoma. [PDF]

Cancer Immunol Immunother
Aoyama S, Noda T, Akita H, Mukai Y, Sasaki K, Hasegawa S, Yamada D, Tomimaru Y, Asaoka T, Takahashi H, Kobayashi S, Shimizu J, Ueyama A, Saito T, Kido K, Morii E, Wada H, Doki Y, Eguchi H.   +18 more
europepmc   +1 more source

Hipo 5 Presentes futuribles, futuros presentables/Futurable Presents, Presentable Futures

, 2017
García Triviño, Francisco Antonio, Psegiannaki, Katerina, Nieto Fernandez, Fernando   +3 more
openaire   +1 more source

Comparative genomics reveals avian Acinetobacter baumannii as antimicrobial resistance reservoirs and bovine strains with elevated pathogenicity. [PDF]

Sci Rep
Bhargavi D, Ghatak S, Srinivas K, Angappan M, Pyngrope DA, Lamare JP, Das S, Milton AAP, Prasad CB.   +8 more
europepmc   +1 more source

Poster Presentation

Experimental Animals, 2019
openaire   +3 more sources